Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Over 1,500 people from around the world attended MAPS’ Psychedelic Science 2013 conference in Oakland, CA. Lyle Craker, Ph.D., Reddit awarded $82,765.95

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

The Herb Collective

JUNE 25, 2018

In 2013, of the estimated 22 million pounds of US grown marijuana each year, Kentucky, California, Tennessee, Hawaii, and Washington grew roughly 80% of all crops. Million in Medicare was saved in 2013 after states implemented medical marijuana laws. patients per thousand residents in Colorado, 19.4 (Source: Leafly) 3.

Marijuana 56

Marijuana Edibles Recreational Strains 56

Canna Law Blog

SEPTEMBER 28, 2019

Not long ago we wrote about a decision by the Second Circuit that may force the DEA to re- or deschedule marijuana after writing about the lawsuit when it was first filed last year. Student”) was born in 2013. In 2016, the Albuquerque Public Schools (“APS”) informed Mother that Student could not receive cannabis oil on school grounds.

Education 61

Education Oil DEA Cannabis 61

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

DECEMBER 1, 2019

Barr stated, “I am not going to go after companies that have relied on the Cole memorandum,” referring to the 2013 Obama administration policy of not enforcing marijuana prohibition in states where legalization has been established. “To Likewise, in Patients Mutual Assistance Collective Corp. 15, 2019, [link] ). Comm’r (T.C.

Marijuana 59

Marijuana Business State Laws DEA 59

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40